Updated:
Genomatica
Christophe Schilling's Genomatica bio-engineers industrial chemicals for Lululemon, Unilever, and L'Oréal, and was acquired by Ginkgo Bioworks in 2024.
Genomatica
Genomatica was founded in 1998 by Christophe Schilling and Bernhard Palsson as a metabolic-engineering platform spun out of the University of California, San Diego. The firm harnesses engineered microorganisms to ferment plant sugars into widely used industrial chemicals, displacing petroleum-derived equivalents. Its model bridges lab-scale synthetic biology and full commercial production through licensing agreements with established manufacturers. The company has operated for over two decades as a privately held, venture-backed entity without ever pivoting from bio-manufacturing. The firm's strategy centers on engineering microbes to produce molecules identical to petrochemical building blocks at cost parity, targeting three markets: nylon intermediates, household- and personal-care surfactants, and specialty materials. Genomatica shipped the world's first metric ton of bio-based 1,4-butanediol in 2013, a nylon precursor previously made exclusively from hydrocarbons. Its named commercial partners include Lululemon, which uses Genomatica's bio-nylon in athletic apparel; Unilever, for palm-oil-alternative surfactants in soaps and detergents; and L'Oréal, for sustainable palm-kernel-oil substitutes in cosmetics (per Bloomberg, 2022). The company's production footprint stretches across North America and Europe through licensees like Covestro and Cargill. As of 2023, the company had raised roughly $400 million in cumulative equity and deployed capital across demonstration facilities in California and commercial-scale plants co-funded by downstream partners. Genomatica operates from its San Diego headquarters and a process-scale-up center in San Diego's biotech corridor. Adjacent structures include the venture collective Project M, where Genomatica pooled demand from Lululemon, Unilever, and Kao to de-risk a $120 million bio-nylon facility (per Fortune, 2023). In July 2024, Genomatica announced it would be acquired by Ginkgo Bioworks in a deal structured predominantly as Ginkgo stock, marking a consolidation play in the industrial biotech sector (per Reuters, July 2024). The firm's structural differentiator is its pure technology-licensing model: Genomatica does not own or operate commercial plants, instead collecting royalties from manufacturing partners that operate the scaled fermentation assets. This capital-light structure allowed the firm to outlast several capital-intensive competitors in the 2010s bio-fuels bust while maintaining ROE that attracted crossover investors. Its subsequent absorption into Ginkgo Bioworks, a listed synthetic-biology platform, signals the post-VC maturity of the industrial-biotech space and creates a combined entity that controls pathogen engineering, cannabinoid production, and bio-materials under one public-company umbrella.
General information
Firm type
Asset Manager
Year founded
1998
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Diego
Corporate office
San Diego, CA, United States
Principals
Christophe Schilling
Co-Founder & CEO
Sector focus
Frequently asked questions
Who runs investment decisions at Genomatica?
Genomatica was not an investment firm but a biotechnology company. Capital allocation and partnership decisions were led by CEO and co-founder Christophe Schilling, who had run the company since its 1998 founding. The board included representatives from venture backers such as TPG Rise, Casdin Capital, and Viking Global.
How does Genomatica source and validate its technology?
Genomatica's core asset was a proprietary computational platform that models metabolic pathways in microorganisms, predicting which genetic modifications produce a target molecule efficiently. It validated organisms first at bench scale inside its San Diego labs, then scaled through a demonstration facility before transferring the full process to licensees like Cargill and Covestro.
Is Genomatica structured as a venture-backed company or a project-finance vehicle?
Genomatica was a privately held venture-backed corporation. It raised equity from financial sponsors including TPG, Casdin Capital, and Ginkgo Bioworks, and formed a joint venture called Project M with downstream brand partners to de-risk commercial plant construction — but it did not operate as a standalone project-finance entity.
Does Genomatica participate in commodity chemical markets or only specialty materials?
The firm's commercial pipeline targets high-volume commodity intermediates — 1,4-butanediol (nylon) and 1,3-butanediol (personal care) — that command multi-billion-dollar addressable markets. It positions itself at cost parity with petroleum, not as a premium green alternative. Specialty materials like the Brontide brand of butylene glycol for cosmetics represent a higher-margin extension of the same platform technology.
Where does Genomatica's IP sit now that Ginkgo Bioworks acquired the firm?
As of the July 2024 acquisition, Genomatica's full IP estate — including metabolic models, strain libraries, and royalty streams from licensees — is held by Ginkgo Bioworks, the NYSE-listed synthetic biology company. The combined entity incorporates Genomatica's technology alongside Ginkgo's foundry platform and its acquisitions of Zymergen and Patch Biosciences.
Which sectors does Genomatica explicitly avoid?
Genomatica deliberately avoided pharmaceutical and agricultural-commodity markets, focusing exclusively on large-volume industrial chemicals where it could compete on unit economics with petroleum incumbents. It also steered clear of owning commercial manufacturing assets, leaving capex-heavy plant construction to licensees.
How is Genomatica's model different from other industrial biotech firms that failed in the 2010s?
Unlike Amyris and Solazyme, which burned billions building their own fuel refineries and pivoted to consumer brands, Genomatica ran an asset-light licensing model. It collected royalties from chemical manufacturers rather than competing with them, which let it survive the bio-fuels capital drought that bankrupted multiple peers between 2015 and 2020.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: